Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study
Authors:
- Peter DallPDPeter Dall
- Thorsten KochTKThorsten Koch
- Thomas GöhlerTGThomas Göhler
- Johannes SelbachJSJohannes Selbach
- Andreas AmmonAAAndreas Ammon
- Jochen EggertJEJochen Eggert
- Nidal GazawiNGNidal Gazawi
- Daniela RezekDRDaniela Rezek
- Arthur WischnikAWArthur Wischnik
- Carsten HielscherCHCarsten Hielscher
- Nicolas SchleifNSNicolas Schleif
- Ursula CirrincioneUCUrsula Cirrincione
Open Access
- 8 January 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-7
Abstract
The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clinical studies. An observational study database of patients with EBC receiving trastuzumab-containing (neo)adjuvant therapy was screened to identify those patients who did not receive cytostatic agents. Of 3935 patients, 232 (6%) were identified who received no chemotherapy, being characterized by older age, worse performance status, and/or less aggressive histology. Relapse-free survival in this cohort was 84% (95% confidence interval [CI] 78–89%) at 3 years and 80% (95% CI 74–87%) at 5 years. However, these rates were significantly worse than those in the group of patients who received chemotherapy (hazard ratio 1.49; 95% CI 1.06–2.09; P = 0.022). A similar pattern was observed for overall survival, with marginally non-significant inferiority in the group receiving no chemotherapy (hazard ratio 1.56; 95% CI 1.00–2.44; P = 0.052). Survival rates in patients receiving no chemotherapy were 93% (95% CI 88–97%) and 87% (95% CI 81–93%) at 3 and 5 years, respectively. These findings were confirmed by a propensity score analysis accounting for selection bias. Trastuzumab plus chemotherapy should remain the preferred option in all patients with HER2-positive EBC with an indication for adjuvant treatment. However, a limited proportion of patients will need an alternative treatment approach, either because of contraindications or the patient’s preference. In these selected patients, trastuzumab monotherapy, eventually combined with endocrine agents, might be a reasonable option offering favorable long-term outcomes by addressing the high-risk profile associated with HER2-positive disease.Keywords
Funding Information
- Roche Pharma AG, Germany
This publication has 26 references indexed in Scilit:
- Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trialsCancer Treatment Reviews, 2013
- Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer networkBritish Journal of Cancer, 2011
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?The Breast, 2011
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31Journal of Clinical Oncology, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or SmallerJournal of Clinical Oncology, 2009
- Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast CancerJournal of Clinical Oncology, 2009
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyJournal of Clinical Oncology, 2009
- Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumoursBritish Journal of Cancer, 2009